Thrombocytopenia and hemostatic disorders in chronic graft versus host disease

Bone Marrow Transplantation

Volumn 44, Issue 7, 2009, Pages 393-403

  Pulanic, D ^a,b   Lozier, J N ^a   Pavletic, S Z ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CLOTTING DISORDER; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; GRAFT FAILURE; HUMAN; HYPERSPLENISM; IMMUNOPATHOLOGY; INFECTION; MICROANGIOPATHY; PATHOPHYSIOLOGY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; GRAFT VS HOST DISEASE; HEMOSTATIC DISORDERS; HUMANS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 70350347997     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.196     Document Type: Review

References (113)

1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol 2006; 13: 426-435.
2. Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 2005; 78: 265-274.
3. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
4. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ. Transplantation's greatest challenges: Advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 2-10.
5. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73: 1054-1058.
6. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood 2003; 102 802-809.
7. Akpek G, Zahurak ML, Piantadosi S, Marglois J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226.
8. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
9. Arora M, Burns LI, Davies SM, MacMillan ML, Defor TE, Miller WJ et al Chronic graft-versus-host disease: A prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38-45.
10. Arora M, Nagaraj S, Wagner JE, Barker JN, Brunstein CG, Burns LJ et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): Higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant 2007; 13: 1145-1152.
11. Pasquini MC. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008; 21: 193-204.
12. Sullivan KM, Withenspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S et al. Prednisone and azathioprine compared to prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonge thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-554.
13. Nash RA, Gooley T, Davis C, Appelbaum FR. The problem of thrombocytopenia after hematopoietic stem cell transplantation. Oncologist 1996; 1: 371-380.
14. First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985; 65: 368-374.
15. Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host disease: Implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645-651.
16. Seidler CW, Mills LE, Flowers MED, Sullivan KM. Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. Am J Hematol 1994; 45: 240-243.
17. Lazarchick J, Green C. Acquired von Willebrand's disease following bone marrow transplantation. Ann Clin Lab Sci 1994; 24: 211-215.
18. Ritchie DS, Sainani A, D'Souza A, Grigg AP. Passive donor-to-recipient transfer of antiphospholipid syndrome following allogeneic stem-cell transplantation. Am J Hematol 2005; 79: 299-302.
19. Kasamon KM, Drachenberg CI, Rapoport AP, Badros A. Catastrophic antiphospholipid syndrome: Atypical presentation in the setting of chronic graft versus host disease: Case report and review of the literature. Haematologica 2005; 90: E50-e53.
20. Sohngen DHA, Meckenstock G, Aul C, Wolf HH, Schneider W, Specker C et al. Antiphospholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. Am J Hematol 1994; 47: 143-144.
21. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R et al Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154-162.
22. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
23. Holmberg LA, Torok-Storb B. Possible role of a defective hematopoietic microenvironment for the pathogenesis of bone marrow failure. In: Raghavachar A, Schrezenmeier H, Frickhofen N (eds). Aplastic Anemia: Current Perspectives on the Pathogenesis and Treatment. Blackwell MZV: Vienna, Austria, 1993, pp 58-66.
24. Peralvo J, Bacigalupo A, Pittaluga PA, Occhini D, Van Lint MT, Frassoni F et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 279-285.
25. Koç ON, Lazarus HM. Mesenchymal stem cells: Heading into the clinic. Bone Marrow Transplant 2001; 27 (3): 235-239.
26. Lazarus HM, Koç ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11 (5): 389-398.
27. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81 (10): 1390-1397.
28. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18 (2): 307-316.
29. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371 (9624): 1579-1586.
30. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: Real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709-719.
31. Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B et al Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-2024.
32. Rabinowe SN, Soiffer RJ, Tarbell NJ, Neuberg D, Freedman AS, Seifter J et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77: 1837-1844.
33. Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701-706.
34. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47-55.
35. Pihusch R, Salat C, Schmidt E, Göhring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.
36. Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78 (6): 911-918.
37. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
38. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
39. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
40. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
41. Basara N, Blau WI, Römer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22 (1): 61-65.
42. Diz-Küçükkaya R, Gushiken FC, López JA. Thrombocytopenia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds). Williams Hematology, 7th edn. The McGraw-Hill Companies, Inc.: New York, NY, 2006 pp 1749-1783.
43. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica 2008; 93: 1702-1711.
44. Benda H, Panzer S, Kiefel V, Mannhalter C, Hinterberger W, Lechner K. Identification of the target platelet glycoprotein in autoimmune thrombocytopenia occurring after allogeneic bone marrow transplantation. Blut 1989; 58: 151-153.
45. Bierling P, Pignon JM, Kuentz M, Mitjavila MT, Fromont P, Barbu V et al. Thrombocytopenia after bone marrow transplantation caused by a recipient origin Br(a) allo-anti-body: Presence of mixed chimerism 3 years after the graft without hematologic relapse. Blood 1994; 83: 274-279.
46. Evenson DA, Stroncek DF, Pulkrabek S, Perry EH, Radford J, Miller JS et al. Posttransfusion purpura following bone marrow transplantation. Transfusion 1995; 35: 688-693.
47. Banaji M, Bearman SI, Buckner CD, Clift RA, Bensinger WI, Petersen FB et al. The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation. Am J Hematol 1986; 22: 275-283.
48. Kalhs P, Schwarzinger I, Anderson G, Mori M, Clift RA, Storb R et al A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86: 2028-2032.
49. Proleznik Zupan I, Prentice HG, Pretnar J, Zver S, Cernelc P. Splenectomy for severe autoimmune cytopenias after allogeneic stem cell transplantation: Case report. Int J Hematol 2005; 82: 75-78.
50. Poskitt TR, Poskitt PK. Thrombocytopenia of sepsis: The role of circulating IgG-containing immune complexes. Arch Intern Med 1985; 145: 891-894.
51. Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R et al. Infectious complications in chronic graft-versus-host disease: A retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transpl Infect Dis 2008; 10: 252-259.
52. Baker GR, Levin J. Transient thrombocytopenia produced by administration of macrophage colony-stimulating factor: Investigations of the mechanism. Blood 1998; 91: 89-99.
53. Nash RA, Burstein SA, Storb R, Yang W, Abrams K, Appelbaum FR et al Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: Increased destruction of circulating platelets. Blood 1995; 86: 1765-1775.
54. Johnson CW, Nachtman JP, Cimprich RE, Moon HL, Mills SE, Beckendorf J et al. Clinical and histopathological effects of M-CSF in laboratory animals. Int Rev Exp Pathol 1993; 34: 189-204.
55. Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus (CMV) genotypes with death from myelosuppression after marrow transplantation. Blood 1997; 90 2097-2102.
56. Forman SJ, Zaia JA, Racklin BC, Wright CL, Blume KG. In vitro suppression of bone marrow growth (CFU-c) by human cytomegalovirus antigen stimulated mononuclear cells and supernatant. Blood 1985; 66: 259a.
57. Verdonck LF, van Heugten H, de Gast GC. Delay in platelet recovery after bone marrow transplantation: Impact of cytomegalovirus infection. Blood 1985; 66: 921-925.
58. Rosenfeld SJ, Young NS. Viruses and bone marrow failure. Blood Rev 1991; 5: 71-77.
59. Sing GK, Ruscetti FW. Preferential suppression of myelopoiesis in normal human bone marrow cells after in vitro challenge with human cytomegalovirus. Blood 1990; 75: 1965-1973.
60. Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, Jeor St SC. Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 1992; 80: 170-178.
61. Duncombe AS, Grundy JE, Prentice HG, Brenner MK. IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant 1991; 7: 81-87.
62. Apperley JF, Dowding C, Hibbin J, Buiter J, Matutes E, Sissons PJ. The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol 1989; 17: 38-45.
63. Smirnov SV, Harbacheuski R, Lewis-Antes A, Zhu H, Rameshwar P, Kotenko SV. Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: Implications for hematopoiesis, self-renewal and differentiation potential. Virology 2007; 360 (1): 6-16.
64. Broxmeyer HE, Dent A, Cooper S, Hangoc G, Wang ZY, Du W et al. A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus. Exp Hematol 2007; 35 (Suppl 1): 87-93.
65. Zhong J, Khanna R. Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 2007; 5 (3): 449-459.
66. Takami A, Mochizuki K, Ito S, Sugimori C, Yamashita T, Asakura H et al. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation. Transplant Proc 2007; 39 (1): 237-239.
67. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 2008; 8 (10): 2111-2118.
68. Walter RB, Hong TC, Bachli EB. Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. Ann Hematol 2002; 81: 672-675.
69. Isomura H, Yoshida M, Namba H, Fujiwara N, Ohuchi R, Uno F et al. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro. J Gen Virol 2000; 81 663-673.
70. Bhattacharyya J, Kumar R, Tyagi S, Kishore J, Mahapatra M, Choudhry VP. Human parvovirus B19-induced acquired pure amegakaryocytic thrombocytopenia. Br J Haematol 2005; 128: 128-129.
71. Sipahi T. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2005; 22: 345-346.
72. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: A review of 98 cases. Clin Infect Dis 2006; 43 40-48.
73. Takatsuka H, Wakae T, Mori A, Okada M, Fujimori Y, Takemoto Y et al Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31: 475-479.
74. Bunn Jr PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: 1632-1641.
75. Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F et al Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994; 12: 2667-2676.
76. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort Jr R et al. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: A phase I study. J Clin Oncol 1992; 10: 1643-1649.
77. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
78. Storek J, Witherspoon RP, Maloney DG, Chauncey TR, Storb R. Improved reconstitution of CD4T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood 1997; 89: 3891-3893.
79. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A et al. TGF-beta in allogeneic stem cell transplantation: Friend or foe? Blood 2005; 106: 2206-2214.
80. Sakamaki S, Hirayama Y, Matsunaga T, Kuroda H, Kusakabe T, Akiyama T et al. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood 1999; 94: 1961-1970.
81. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59-65.
82. Tabata T, Kawakatsu H, Maidji E, Sakai T, Sakai K, Fang-Hoover J et al. Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production. Am J Pathol 2008; 172 (4): 1127-1140.
83. Hirayama Y, Sakamaki S, Tsuji Y, Sagawa T, Chiba H, Matsunaga T et al Thrombopoietin concentrations in peripheral blood correlated with platelet numbers in two patients with thrombocytopenia by chronic graft-versus-host disease. Am J Hematol 2003; 73: 285-289.
84. Pihusch R, Wegner H, Salat C, Pihusch M, Holler E, Kolb HJ et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 381-387.
85. Van Wijk MJ, vanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular disease. Cardiovasc Res 2003; 59: 277-287.
86. Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-194.
87. Warner MN, Pavord S, Moore JC, Warkentin TE, Hayward CP, Kelton JG. Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders. J Lab Clin Med 1999; 133: 129-133.
88. Gilbert GE, Sims PJ, Widemer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for Factor VIII. J Biol Chem 1991; 266: 17261-17268.
89. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-18212.
90. Barry OP, Practico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-2127.
91. Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Hemost 1996; 75: 427-431.
92. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-3456.
93. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-848.
94. Weber A, Koppen HO, Schror K. Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res 2000; 98: 461-466.
95. Andrews RK, Berndt MC. Microparticles facilitate neutrophil/platelet crosstalk. Blood 2008; 112: 2174-2175.
96. Pluskota E, Woody NM, Szpak D, Ballantyne CM, Soloviev DA, Simon DI et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood 2008; 112 2327-2335.
97. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-2083.
98. Pihusch V, Rank A, Steber R, Pihush M, Pihush R, Toth B et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006; 81: 1405-1409.
99. Saelman EUM, Nieuwenhuis HK, Hese KM, de Groot PG, Heijnen HF, Sage EH et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood 1994; 83: 1244-1250.
100. Handa M, Watanabe K, Kawai Y, Kamata T, Koyama T, Nagai H et al. Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Hemost 1995; 73: 521-528.
101. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: A defect in platelet spreading. Blood 1986; 68: 692-695.
102. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
103. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA et al Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995-3996.
104. Mengarelli A, Minotti C, Palumbo G, Arcieri P, Gentile G, Iori AP et al. High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation. Br J Haematol 2000; 108 126-131.
105. Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E et al. Megakaryocyte-derived microparticles: Direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113: 1112-1121.
106. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
107. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100: 728-730.
108. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
109. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741.
110. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628-638.
111. Tiu RV, Sekeres MA. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opin Biol Ther 2008; 8: 1021-1030.
112. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: A review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-912.
113. Kobos R, Bussel JB. Overview of thrombopoietic agents in the treatment of thrombocytopenia. Clin Lymphoma Myeloma 2008; 8: 33-43.